StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Equities researchers at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.57 on Friday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm’s 50 day moving average is $0.69 and its 200-day moving average is $0.67. The firm has a market capitalization of $53.03 million, a price-to-earnings ratio of -1.59 and a beta of 1.17.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC grew its position in VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the period. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.